Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BCAX declined for three days, in 97 of 109 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCAX as a result. In 26 of 32 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Aroon Indicator for BCAX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCAX's RSI Indicator exited the oversold zone, 6 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 20 of 26 cases where BCAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for BCAX just turned positive on October 13, 2026. Looking at past instances where BCAX's MACD turned positive, the stock continued to rise in 15 of 18 cases over the following month. The odds of a continued upward trend are 83%.
Following a +6.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAX advanced for three days, in 99 of 122 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
BCAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.654) is normal, around the industry mean (26.782). P/E Ratio (3.414) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BCAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for RAPP entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 62 similar instances where the Aroon Indicator formed such a pattern. In 56 of the 62 cases the stock moved lower. This puts the odds of a downward move at 90%.
RAPP moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RAPP crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. RAPP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.794) is normal, around the industry mean (26.782). P/E Ratio (21.808) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| BCAX | RAPP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | N/A |
| Momentum ODDS (%) | 6 days ago 81% | N/A |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| Advances ODDS (%) | 6 days ago 81% | N/A |
| Declines ODDS (%) | 8 days ago 89% | 1 day ago 77% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCAX’s FA Score shows that 1 FA rating(s) are green while RAPP’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCAX’s TA Score shows that 5 TA indicator(s) are bullish while RAPP’s TA Score has 2 bullish TA indicator(s).
BCAX (@Biotechnology) experienced а +5.60% price change this week, while RAPP (@Biotechnology) price change was -8.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
BCAX is expected to report earnings on Nov 17, 2026.
RAPP is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with CLDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To BCAX | 1D Price Change % | ||
|---|---|---|---|---|
| BCAX | 100% | N/A | ||
| CLDX - BCAX | 46% Loosely correlated | -1.47% | ||
| RCUS - BCAX | 44% Loosely correlated | +0.09% | ||
| BCYC - BCAX | 43% Loosely correlated | -3.31% | ||
| RAPP - BCAX | 42% Loosely correlated | -2.28% | ||
| CGON - BCAX | 42% Loosely correlated | -0.90% | ||
More | ||||
A.I.dvisor indicates that over the last year, RAPP has been loosely correlated with CGEM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RAPP jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To RAPP | 1D Price Change % | ||
|---|---|---|---|---|
| RAPP | 100% | -2.28% | ||
| CGEM - RAPP | 49% Loosely correlated | -3.26% | ||
| AVTX - RAPP | 44% Loosely correlated | -1.42% | ||
| CLDX - RAPP | 44% Loosely correlated | -1.47% | ||
| IMRX - RAPP | 43% Loosely correlated | -3.93% | ||
| IMMX - RAPP | 43% Loosely correlated | -2.07% | ||
More | ||||